Wednesday, April 7, 2010 as of 11:14 AM ET
A Food and Drug Administration (FDA) advisory committee recommended Thursday the agency approve a new drug to treat obesity, the second time this year agency advisers have backed a fat-fighting medication.
Arena Pharmaceuticals Inc. makes the drug, lorcaserin, and hopes to market it under the brand name Lorqess.The advisory committee voted 18-4, with one abstention, that the weight loss benefits of the medication outweigh any possible risk.Research showed signs the medicine might be linked to a small risk of cancer and heart valve disease.In February, an advisory committee recommended the agency approve Vivus Inc.'s Qnexa drug for weight loss. The agency has not acted on it yet.Lorcaserin was rejected in 2010 by the federal agency, which cited "modest weight loss" and concerns about a study that linked the drug to mammary tumors in rats.This time, Arena returned to the FDA with new data showing that 38 percent of patients on the drug had weight loss of five percent or more in a year, co...Sugar, as we've long been told by our mothers and doctors, rots your teeth, causes acne and leads to obesity and diabetes. But does it actually make you stupid? That...
"Maxed out on the medications" is how Bill Ezzell describes his struggle with blood pressure. It's dangerously high even though the North Carolina man swallows six d...
Imagine a tiny snake robot crawling through your body, helping a surgeon identify diseases and perform operations.It's not science fiction. Scientists and doctors ar...
The Food and Drug Administration is considering approval of the first over-the-counter HIV test that would allow consumers to quickly test themselves for the virus a...
A U.S. health advisory panel on Thursday issued a split vote on data for Pfizer Inc's drug to treat a rare neurodegenerative disease.The U.S. Food and Drug Administr...
Martha Stewart, on Wednesday, was named as non-executive chairman of the lifestyle, media and merchandising company that she created.Stewart rejoined the board of Ma...
Martha Stewart is now the non-executive chairman of the lifestyle, media and merchandising company that she created.Stewart, who rejoined the board of Martha Stewart...
A Food and Drug Administration panel of outside experts on Thursday ruled against using a pain-relief product derived from chili peppers to treat the pain that affli...
Stimulants used to treat attention deficit hyperactivity disorder do not increase the risk of heart attacks, strokes or sudden death, U.S. researchers said on Monday...
A US Food and Drug Administration (FDA) advisory panel will decide this week whether to recommend for the first time that certain healthy but at-risk people take a d...
Health regulators said on Monday they could not definitively link Novartis AG's multiple sclerosis pill Gilenya with the deaths of people who took the drug.The Food ...
News about gross-out ingredients like pink slime and ammonia (more about both later) got us thinking: What other surprises lurk in the food we eat? We put that quest...
Sanofi reported positive results from a late-stage trial of its Aubagio multiple sclerosis drug, bolstering its chances of approval by regulators as it seeks to catc...
A Texas urologist and his attorney wife who are accused of violating a U.S. trade embargo with Iran also face federal charges that they defrauded government and priv...
At the Henry Ford Hospital in Detroit, pharmacists are using old-fashioned paper spreadsheets to track their stock of drugs in short supply - a task that takes sever...
High fructose corn syrup won't get a wholesome new name after all.The Food and Drug Administration on Wednesday rejected the Corn Refiners Association's bid to renam...
An FDA advisory committee will meet in the second quarter to discuss Arena Pharmaceutical Inc's experimental obesity drug following the company's recent resubmission...
Some websites are peddling fake versions of Adderall, a treatment for attention deficit hyperactivity disorder that is currently in short supply in the United States...
U.S. drug regulators chided a Johnson & Johnson unit for not reporting or investigating customer complaints about O.B. Tampons or personal lubricants similar to K-Y ...
This material may not be published, broadcast, rewritten, or redistributed. ©2012 FOX News Network, LLC. All rights reserved. All market data delayed 20 minutes.
